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Stent implantation has become the new standard angioplasty procedure. In-
stent re-stenosis remains the major limitation of coronary stenting. Re-stenosis is
related to patient-, lesion- and procedure-specific factors.
Patient-specific factors can not be influenced to any extent. Procedure-specific
factors are affected by implantation technique and stent characteristics. Design
and material influence vascular injury and humoral and cellular response.
Radiation has been shown to have inhibitory effects on smooth muscle cell
growth and neo-intima formation, but in clinical trials the outcome has been
hampered by re-stenosis at the edges of the radioactive stent (‘candy wrapper’).
New approaches target pharmacological modulation of local vascular biology
by local administration of drugs. This allows for drug application at the precise
site and time of vessel injury. Systemic release is minimal and this may reduce
the risk of toxicity. The drug and the delivery vehicle must fulfil pharmaco-
logical, pharmacokinetic and mechanical requirements and the application of
eluting degradable matrices seems to be a possible solution. Numerous
pharmacological agents with antiproliferative properties are currently under
clinical investigation, e.g. actinomycin D, rapamycin or paclitaxel. Another
approach is for stents to be made of biodegradable materials as an alternative
to metallic stents. Their potential long-term complications, such as in-stent re-
stenosis and the inaccessibility of the lesion site for surgical revascularization,
needs to be assessed.
Current investigational devices and the line of (pre)clinical investigation are
discussed in detail. Currently, there is little experimental, and only preliminary
clinical, understanding of the acute and long-term effects of drug-eluting or
biodegradable stents in coronary arteries. The clinical benefit of these
approaches still has to be proven.
Over the last decade, coronary stents have revolutionized the field of
interventional cardiology. Stent implantation has become the new
standard angioplasty procedure1–3. This popularity is mainly for two
reasons: (i) the unique capability to master a major complication of
balloon angioplasty – (sub)acute vessel closure; and (ii) a superior long-
term outcome in comparison to balloon angioplasty4–8. The high
reliability of the acute angioplasty result after stenting allowed for a
dramatic expansion in the indication for catheter-based intervention
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(ostial lesions9, bifurcation lesions10,11, left main lesions12,13, multiple
lesions14).
In the early phase, device technology was directed toward improving
the accessibility of lesions, e.g. in tortuous, small and/or calcified vessels.
The advances included premounted stents, reduced crossing profile and
improved flexibility. Modifications in stent design such as ‘rotating’ and
‘locking’ mechanisms afforded them high flexibility when unexpanded
and remarkable radial strength when expanded. Further development
included specifically configured stents for distinct indications, such as
bifurcation lesions, lesions with side branch take-off, aneurysms and
vessel rupture.
The problem: re-stenosis
As most acute aspects of stenting are resolved, the long-term outcome
becomes more and more the focus of attention. In-stent re-stenosis
remains for several reasons the major limitation of coronary stenting.
The absolute number of in-stent re-stenotic lesions is increasing in
parallel with the steadily increasing number of stenting procedures and
with the complexity of culprit lesions. The treatment of in-stent re-
stenosis is, despite progresses in radiation therapy, technically
challenging and costly. In subsets of lesions (such as small vessel size and
diffuse disease), an anticipated high risk for re-stenosis may prevent the
use of stents. 
Re-stenosis is considered as a local vascular manifestation of the general
biological response to injury. Catheter-induced injury consists of denud-
ation of the intima and stretching of the media. The wound-healing
reaction consists in an inflammatory phase, a granulation phase and a
remodelling phase. The inflammatory phase is characterized by platelets
and growth factor activation, the granulation phase by smooth muscle cell
and fibroblast migration and proliferation into the injured area, the
remodelling phase by proteoglycan and collagen synthesis, which replaces
early fibronectin as major component of extracellular matrix15. Current
concepts describe three mechanisms of the re-stenotic process: early elastic
recoil, late vessel remodelling and neo-intimal growth16,17. Coronary stents
provide mechanical scaffolding that virtually eliminates recoil and
remodelling18. However, neo-intimal growth continues to be a major
problem.
Neo-intimal proliferation occurs principally, but not exclusively, at the
site of the primary lesion within the first 6 months after stent
implantation. Neo-intima is basically an accumulation of smooth muscle
cells within a proteoglycan matrix that narrows the previously enlarged
lumen. Neo-intima formation is triggered by a cascade of cellular and
Ischaemic heart disease: therapeutic issues
British Medical Bulletin 2001;59
14 Serruys.QXD  3/12/01 5:44 pm  Page 228
 at Institute of Social Studies on N
ovem
ber 26, 2015
http://bm
b.oxfordjournals.org/
D
ow
nloaded from
 
229
molecular events including platelet activation, leukocyte infiltration,
smooth muscle cell expansion, extracellular matrix elaboration and re-
endothelialization.
In the clinical setting, neo-intimal formation and in-stent re-stenosis
are related to patient-specific factors such as genetic predisposition or
diabetes mellitus19, to lesion-specific factors such as vessel calibre20,
lesion length or plaque burden 21 and to procedure-specific factors such
as extent of vessel damage, residual dissections22, number of stents,
minimal stent diameter or minimal stent area23.
Patient-specific factors can not be influenced to any extent. Attempts
to modulate lesion-specific factors by pharmacological therapy have not
been not successful so far24,25. Procedure-specific factors may be
favourably affected by the stent implantation technique and stent
characteristics26.
The solution: the ideal stent?
From the interventionist’s technical point of view, the ideal stent should
have at least the following features:
• Reach any location within the coronary artery system
• Have a low profile, high trackability and flexibility
• Allow for precise placement with good visibility
• Guarantee predictable expansion with minimal foreshortening
• Provide equally distributed radial strength, be rigid and have many, thick struts
• Prevent plaque protrusion having many struts with small spaces between struts
• Allow for side-branch access having few struts with large spaces between struts
• Reduce acute thrombotic and inflammatory vessel response, i.e. have few, 
thin struts
• Allow wound healing but inhibit exaggerated neo-intimal growth. It should be
thromboresistant and have high hydrodynamic compatibility
• Guarantee vessel accessibility for further intervention (PCR, bypass grafting)
and thus possibly disappear after 6 months.
Unfortunately, all these requirements on stent characteristics are
mutually incompatible.
The ideal stent: small steps towards a big goal
The focus of stent development in the first decade of stenting was on
optimization of stent characteristics. Systematic investigations were
performed to gain insights into mechanisms of stent action and vessel
biology. This resulted in a huge variety of stents, differing in design,
material, surface, radioactivity and coatings27.
Stent development and local drug delivery
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Design
Stent design varies in the geometry (number of intersections and interstrut
area), in the strut configuration and the metal-to-artery ratio. These are the
major determinants of stent profile, flexibility, radial strength and (elastic)
expansion characteristics.
Presently, more than 55 stents are available (12 with FDA-approval)
which are manufactured by more than 30 companies. They use two
different expansion principles (balloon-expansion and self-expansion) and
can be categorized in five basic design types: tubular, ring, multi-design,
coil, and mesh.
The physical properties affect vascular injury and response. The different
stent designs show a considerable range of the elastic moduli28 which affect
stent expansion properties as late as 8 weeks after deployment29. Reduction
of strut–strut intersections can reduce the vascular injury score, thrombosis
and neo-intimal hyperplasia30. Non-uniform stent expansion increases
vascular injury and in-stent re-stenosis31.
Material and surface (texture)
Stent materials and surface are relevant to in-stent re-stenosis. Surface
characteristics can be modulated by (electromechanical) polishing, ion
implantation or coating. Suitable stent materials are metals, metal-alloys
or polymers. Chemistry, charge, and texture32 modulate humoral and
Ischaemic heart disease: therapeutic issues
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Fig. 1 Coronary angiogram of a the left coronary artery, showing a lesion of the
circumflex artery pre-intervention (left), immediately after radioactive stent implantation
(mid) and at 6-months’ follow-up (right). At 6 months, there is significant narrowing at
the proximal and at the distal edge of the radioactive stent (‘candy wrapper’ effect), while
the lumen within the stent shows only minimal neo-intimal growths.
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cellular vessel response (plasma proteins, inflammatory and proliferative
mediators, platelet and leukocyte activation). Copper is more frequently
associated with subacute thrombosis than steel33.
Radioactivity
Another possible way to modify the physical properties is the
introduction of radioactivity34,35. Radiation has proven inhibitory effects
on smooth muscle cell growth and neo-intima formation36. However,
clinical trials utilizing radioactive stents have been disappointing.
Despite effective prevention of neo-intimal growth with the stent,
clinical and angiographic outcomes have been hampered by re-stenosis
at the edges of the radioactive stent; termed the ‘candy wrapper’ effect
(Fig. 1)37. This unfavourable phenomenon occurred irrespective of the
stent design (cold end, hot end) or the dose rate (high activity versus low
activity; Table 1).
Coating
Coating categories are various (Table 2). Stent coatings can dramatically
reduce protein deposition and platelet adhesion in experimental settings
(Fig. 2)38. However, polymers have shown conflicting results in the
experimental setting39–41 with some provoking a severe tissue response42.
Stent development and local drug delivery
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Table 1 Results of [32P]-radioactive stents at 6-month follow-up
Study Patients Stent activity Lesion length Restenosis TLR
(n) (µCi) (mm) rate
IRIS 1A 32 0.5–1.0 <15 31 21
IRIS 1B 25 0.75–1.5 <15 50 32
IRIS Heidelberg 11 1.5–3.0 <15 54 N/A
IRIS Rotterdam 26 0.75–1.5 <28 17 12
[32P]-Dose response Rotterdam 40 6.0–12 <28 44 25
[32P]-Dose Response Milan 23 0.75–3.0 <28 52 52
29 3.0–6.0 41 41
30 6.0–12 50 50
40 12–21 30 30
N/A, not available; TLR, target lesion revascularization.
Table 2 Stent coating categories
Inorganic/ceramic materials Gold, si-carbide, diamond-like carbon, biogold
Synthetic and biological polymers Phosphorylcholine, polyurethane, polyester, polylactic 
acid, cellulose
Human polymers Chondroitin sulphate, hyaluronic acid, fibrin
Immobilized drugs Heparin, paclitaxel, abciximab, P-15 (peptide)
Membrane-covered PTFE, autologous vein and artery
Eluting, degradable matrices
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A number of other coatings like inert polymer30, phosphorylcholine43,44
or heparin45–47, demonstrated a reduction in (sub)acute stent thrombosis
rate and possible effects on neo-intimal hyperplasia48.
In clinical practice, however, the acute beneficial effect on stent
thrombosis is of minor relevance as already modern uncoated stents show
a very low (sub)acute thrombosis rate. Furthermore, the acute beneficial
effect did not result in a substantial decrease in in-stent re-stenosis49. In
response to this, the interest in coatings has shifted towards considering
coatings as vehicles for local drug delivery. So far, phosphorylcholine is the
only clinically-available, polymer coated stent (Fig. 3)50.
A big step: local drug delivery?
New approaches target not only the stent characteristics but also the
pharmacological modulation of the local vascular biology. A proposed
Ischaemic heart disease: therapeutic issues
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Fig. 2 SEM of a
heparin coated (left)
and a non-coated
stent.
Fig. 3 Phosphoryl-
choline-coated stent
(BiodivYsioTMTM SV
stent; Biocompatibles
Ltd, Surrey, UK).
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explanation for the repeated failure of clinical drug studies has been that
agents given systemically cannot reach sufficient levels in injured arteries
to impact significantly on the re-stenotic process. Local administration
of drugs offers advantages. The active drug is applied to the vessel at the
precise site and at the time of vessel injury. Local drug delivery might be
able to achieve higher tissue concentrations of the drug. No additional
materials or procedures are required. Systemic release is minimal and
may reduce the risk of remote or systemic toxicity.
Candidate delivery vehicles
The delivery vehicle must fulfil pharmacological, pharmacokinetic and
mechanical requirements. The release of the drug into the vessel must
take place in a manner that is consistent with the drug’s mode of action.
Drug-release must be in predictable and controllable concentrations and
within a known time span. The delivery vehicle must be suitable for
sterilisation. It must follow the stent changes of configuration during
stent expansion and resist mechanical injury caused by the implantation
balloon. An example of possible deleterious effects of stent expansion
and sterilisation on the coating is given in Figure 4. Currently, these
problems are controlled, guaranteeing intact coating during clinical
application (Fig. 5). The application of eluting, degradable matrices
seems to be a possible solution. An overview of delivery vehicles for drug
eluting systems is given in Table 3.
Candidate drugs
The drug should be able to inhibit the multiple components of the complex
re-stenosis process. Uncontrolled neo-intima tissue accumulations shows
Stent development and local drug delivery
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Fig. 4 SEM of a
coated stent, showing
the effect of stent
expansion (left) and
the effect of
sterilization (right) on
the coating.
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some parallels to tumour growths; thus, the use of anti-tumour strategies
seems to be a logical choice. Numerous pharmacological agents with
antiproliferative properties have been tested for their potential to inhibit re-
stenosis with mostly disappointing results51. Antimitotic compounds (like
methotrexate and colchicine) have failed to inhibit smooth muscle cell
proliferation and intimal thickening52,53. In contrast, other agents such as
angiopeptin54, GP IIb/IIIa inhibitors or steroids55 56 have shown a promising
inhibitory effect on neo-intimal proliferation. Potential candidates for local
drug delivery are given in Table 4. The following drugs are now being tested
in randomized clinical trials.
Ischaemic heart disease: therapeutic issues
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Fig. 5 SEM of a
contemporary coated
and drug loaded
stent. The integrity of
the coating is not
affected by stent
expansion or
sterilization.
Table 3 Overview of drug delivery vehicles
* Polyvinyl pyrolidone/cellulose esters
* Polyvinyl pyrolidone/polyurethane
* Polymethylidene maloleate
* Polylactide/glycoloide co-polymers
* Polyethylene glycol co-polymers
* Polyethylene vinyl alcohol
* Polydimethylsiloxane (silicone rubber)
Antineoplastic
Paclitaxel (Taxol™)
Taxol derivative (QP-2)
Actinomycin D
Vincristine
Antithrombins
Hirudin and iloprost
Heparin
Immunosuppressants
Sirolimus (Rapamycin™)
Tranilast
Dexamethasone
Tacrolimus (FK506)
Collagen synthetase inhibitor
Halofuginone
Propyl hydroxylase
C-proteinase inhibitor
Metalloproteinase inhibitor
AngiopeptinV
VEGF
Table 4 Potential candidates for drug elution
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Actinomycin D (Cosmegen®)
Actinomycin D has been marketed world-wide since the 1960s. It is an
antibiotic used for its antiproliferative properties in the treatment of
various malignant neoplasmas (e.g. Wilms tumour, sarcomas, carcinoma
of testis and uterus). It inhibits the proliferation of cells. Actinomycin D
(C62H86N12O16) forms, via deoxyguanosine residues, a stable complex
with double-stranded DNA and inhibits DNA-primed RNA synthesis.
Rapamycin (Sirolimus; Rapamune®)
Rapamune® is an FDA approved drug for the prophylaxis of renal transplant
rejection in use since 1999. It is a naturally occurring macrocyclic lactone (Fig.
6) which is highly effective in preventing the onset and severity of disease in
several animal models of autoimmune disease, such as insulin-dependent
diabetes mellitus, systemic lupus erythematosus and arthritis.
The class of macrocyclic immunosuppressive agents (rapamycin, cyclo-
sporin A, tacrolimus) bind to specific cytosolic proteins called immuno-
philins to gain their immunosuppressive activity. Rapamycin blocks G1 to
S cell cycle progression (Fig. 7) by interacting with a specific target protein
(mTOR, mammalian target of rapamycin) and inhibiting its activation. The
inhibition of mTOR suppresses cytokine-driven (IL-2, IL-4, IL-7 and IL-15)
T-cell proliferation.
mTOR is a key regulatory kinase and its inhibition has several important
effects including: (i) inhibition of translation of a family of mRNAs that
code for proteins essential for cell cycle progression; (ii) inhibition of IL-2-
induced transcription of proliferating cell nuclear antigen (PCNA) that is
essential for DNA replication; (ii) blocking CD28-mediated sustained up-
regulation of IL-2 transcription in T cells; and (iv) inhibition of the kinase
activity of the cdk4/cyclin D and cdk2/cyclin E complexes, essential for cell
Stent development and local drug delivery
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Fig. 6 Chemical structure of rapamycin (Sirolimus).
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Fig. 7 Schematic of the mechanism
of action of rapamycin within the
cell cycle.
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cycle progression. On overview of rapamycin effects within the cell cycle is
given in Figure 8.
The mechanism of action is distinct from other immunosuppressive drugs
that act solely by inhibiting DNA synthesis, such as mycophenolate mofetil
(CellCept) and azathioprine (Imuran). Rapamycin is synergistic with cyclo-
sporin A and has much lower toxicity than other immunosuppressive agents.
In in vitro and in vivo studies, rapamycin prevents proliferation of T
cells but also proliferation57,58 and migration59 of smooth muscle cells.
Furthermore, rapamycin has been shown to diminish smooth muscle cell
hyperproliferation in several animal models of arteriopathy60–62.
Paclitaxel (Taxol®)
Paclitaxel was originally isolated from the bark of the Pacific Yew. It is
an antineoplastic agent that is currently used to treat several types of
cancer, most commonly breast and ovarian cancer.
Ischaemic heart disease: therapeutic issues
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Fig. 8 The cell cycle: a
functionally
integrated cascade of
positive and negative
regulatory factors.
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It is a diterpenoid with a characteristic taxane-skeleton of 20 carbon
atoms and has a molecular weight of 853.9 Da. Paclitaxel exerts its
pharmacological effects through formation of numerous decentralized
and unorganized microtubules. This enhances the assembly of extra-
ordinarily stable microtubules, interrupting proliferation, migration and
signal transduction63,64 Unlike other antiproliferative agents of the
colchicine type, which inhibit microtubuli assembly, paclitaxel shifts the
microtubule equilibrium towards microtubule assembly. It is highly
lipophylic, which promotes a rapid cellular uptake, and has a long-lasting
effect in the cell due to the structural alteration of the cytoskeleton.
In vitro and in vivo studies have shown that paclitaxel may prevent or
attenuate re-stenosis. Paclitaxel inhibits proliferation and migration of
cultured smooth muscle cells in a dose-dependent manner65. In a rat
balloon injury model, intraperitoneal administration of paclitaxel reduced
neo-intimal area. In a rabbit atherosclerotic model where plaque burden
was increased by electrical injury, local administration of paclitaxel
reduced neo-intimal thickness66,67.
Investigational devices
Actinomycin D: Multi-Link Tetra™-D stent (Guidant, Santa Clara, CA, USA)
The stent is fabricated from medical 316L stainless steel tubing and is
composed of a series of cylindrically oriented rings aligned along a
common longitudinal axis. Each ring consists of 3 connecting bars and 6
expanding elements. The stent is premounted on a delivery catheter.
The antiproliferative drug is actinomycin D. The finished Multi-Link Tetra
stent is coated with a polymer matrix (semicrystalline ethylene-vinyl alcohol
co-polymer: EVAL) containing a maximal dose of 150 µg actinomycin D.
This is equivalent to 20–200 times less than the recommended total human
adult dose of 500 µg/day given intravenously for 5 days.
The delivery catheter is a rapid exchange design (0.014 inch guidewire).
It is equipped with two radiopaque markers located underneath the
balloon to mark the ends of the stent and has a ‘stepped’ balloon design to
optimize stent and balloon shoulder configuration.
NIRx™ – paclitaxel-coated conformer coronary stent (Boston Scientific, USA)
The stent is fabricated from medical 316LS stainless steel. The geometry
is a continuous, uniform, multicellular design with adaptive cells
capable of differential lengthening. This enables the stent to be flexible
in the unexpanded configuration. Stent length is 15 mm. The stent is
premounted on a delivery catheter (Fig. 9).
The antiproliferative drug is paclitaxel. Paclitaxel is incorporated into
a fast-release triblock co-polymer carrier system on the stent. There are
two drug concentration. The ‘low dose’ concentration is 1.0 µg/mm2
Stent development and local drug delivery
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(loaded drug/stent surface area; total dose 85 µg per stent) and gives
sustained release over ~28 days. The ‘moderate dose’ is 2.0 µg/mm2
(loaded drug/stent surface area).and provides a rapid release in the first
24 h, followed by a slower release over the following 28 days.
The delivery catheter is a monorail design (0.014 inch guidewire/7F
guiding catheter). It is equipped with two radiopaque markers located
underneath the balloon to mark the ends of the stent. The delivery
balloon will be 3.0 mm and 3.5 mm in diameter.
Rapamycin-coated BX™ VELOCITY stent (Cordis, Warren, USA)
The stent is fabricated from medical 316LS stainless steel. It is available
in 2 configurations: a 6-cell configuration (expanded diameter 2.5–3.25
mm) and a 7-cell design (expanded diameter 3.5–3.75 mm). Stent length
is 18 mm. The stent is premounted on a delivery balloon with diameters
of 2.5 mm, 3.0 mm and 3.5 mm (Fig. 10).
Ischaemic heart disease: therapeutic issues
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Fig. 10 Rapamycin
coated BX™ VELOCITY
stent (Cordis, 
Warren, USA).
Fig. 9 NIRx™-
Paclitaxel-coated
conformer coronary
stent (Boston
Scientific, USA.
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The antiproliferative drug is rapamycin. The stent contains 140 µg/cm2
which gives a total rapamycin content of 153 µg on the 6-cell stent and 180
µg on the 7-cell stent. The coating formulation consists of 30% rapamycin
by weight in a 50:50 mixture of the polymers polyethylenevinylacetate
(PEVA) and polybutylmethacrylate (PBMA; Fig. 11).
The delivery catheter utilizes a rapid exchange design (0.014 inch
guidewire/7F guiding catheter). It is equipped with two radiopaque
markers located underneath the balloon to mark the ends of the stent.
The delivery balloon will be 3.0 mm and 3.5 mm in diameter.
Clinical studies
Actinomycin D
There is no published research to date documenting the use of
actinomycin D for treatment of coronary artery disease and/or re-
stenosis. A phase 1, randomized clinical trial ACTION (ACTinomycin
eluting stent Improves Outcomes by reducing Neointimal Hyperplasia)
started in June 2001 to evaluate the safety and performance of the
Multi-Link Tetra™-D stent system: 360 patients will be randomized to
receive an actinomycin D coated stent or a non-coated stent for
treatment of de novo lesions in native coronary arteries with a vessel
calibre of 3.0–4.0 mm. Six month angiographic follow-up is expected to
be completed in February 2002, 12-month clinical follow-up up is
expected to be completed in August 2002.
Rapamycin (Sirolimus)
A first clinical application of the rapamycin-coated stents was
performed in Sao Paulo and Rotterdam. Thirty patients with angina
pectoris were electively treated with 2 different formulations of
Stent development and local drug delivery
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• Basecoat = polymer + drug
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• Basecoat = polymer + drug
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• Topcoat = diffusion barrier
Stent
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Fast drug release Slow drug release
Fig. 11 Coating
structure for fast drug
release (left) and slow
drug release (right).
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rapamycin-coated BX™ VELOCITY stents (Cordis) (slow release [SR],
n = 15, and fast release [FR], n = 15). All stents (18 mm) were
successfully delivered, (3.0–3.5 mm vessel calibre) and patients were
discharged without clinical complications. At 4 months angiographic
and IVUS follow-up, there was minimal neo-intimal hyperplasia in both
groups (11.0 ± 3.0% in the SR group and 10.4 ± 3.0% in the FR group,
P = NS) by ultrasound and quantitative coronary angiography (in-stent
late loss, 0.09 ± 0.3 mm [SR] and –0.02 ± 0.3 mm [FR]. No in-stent or
edge re-stenosis was observed. No major clinical events (stent
thrombosis, repeat revascularization, myocardial infarction, death) had
occurred by 8 months68. At 1 year follow-up, IVUS volumetric analysis
and angiography indicated minimal amounts of neo-intimal hyperplasia
that were scarcely different from the 4 month data in both groups, with
some patients showing no evidence of hyperplasia whatsoever. There
were no MACE and no re-stenosis in either of the groups. One late acute
MI occurred in the fast-release group at 14 months69.
The randomized RAVEL study with the rapamycin-coated BX™
VELOCITY balloon-expandable stent in the treatment of patients with de
novo lesions in native coronary arteries is a multicenter, prospective,
randomized double-blind clinical trial comparing bare metal and the drug-
coated stents. A total of 220 patients were randomized for treatment with
either a single rapamycin-coated (140 µg.cm–2) or a bare metal BX™
VELOCITY stent. At 6-month follow-up, the restenosis rate of the treated
group was zero, the loss in minimal lumen diameter was zero, there was
no target lesion reintervention and the event-free survival was 96.5%74.
The SIRIUS study is a multicentre, prospective, randomized double-
blind trial that is being conducted in 55 centres in the USA. Eleven
hundred patients with focal de novo native coronary arterial lesions (2.5
to 3.5 mm diameter, 15 to 30 mm long) will be randomized for
treatment with either rapamycin-coated (109 mg.cm–2) or bare metal
BX™ VELOCITY balloon expandable stents. The primary endpoints of
the SIRIUS trial are target vessel failure (death, myocardial infarction,
target lesion revascularization) at 9 months. In addition, secondary
endpoints are core laboratory analysis of angiographic and intravascular
ultrsound data to determine treatment effects on neointimal hyperplasia
and in-stent restenosis. Clinical follow-up will continue for 3 years in
order to assess late events. In addition to the pivotal RAVEL and SIRIUS
trials, feasibility studies are ongoing to assess efficacy of rapamycin-
coated stents in more complex lesion subsets, such as in-stent restenosis.
Paclitaxel
There are several ongoing clinical trials of paclitaxel-coated stents. In the
TAXUS I trial 61 patients were randomized to receive a paclitaxel-coated
(1.0 µg/mm2) or a bare NIR stent. At 6-month follow-up, no restenosis
Ischaemic heart disease: therapeutic issues
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was seen in the paclitaxel-coated stent group, while the restenosis rate in
the bare stent group was 11%.  The late lumen loss of 0.35±0.47 mm was
significantly lower in the paclitaxel-coated stent group (0.71±0.88 mm).
The Asian ASPECT trial showed a clear dose response. Patients (n = 177)
were randomized to receive a high dose (3.1 µg.mm–2) paclitaxel-coated,
a low dose (1.3 µg.mm–2) paclitaxel-coated, or a bare stent. The restenosis
rate at 6 months was 4%, 12%, and 27%, respectively75. The ongoing
ELUTES trial randomises 180 patients into 5 groups – 4 different dose
levels and a bare stent control group.
In other clinical trials, the taxol derivate QP2 was used. The QP2 pilot
study included 32 patients with de novo or restenosis lesions who
underwent QuaDS-QP2 stent implantation. The stainless steel, slotted
tube stent was 13 or 17 mm in length and coated with multiple ploymer
sleeves that slowly release QP2 (up to 4000 µg). A 2-year follow-up of 25
patients recorded that they were all asymptomatic76. Another group
reported on the 8 month IVUS follow-up. IVUS revealed only moderate
neointima formation with a neointima burden of 13.6±14.9%77. Another
multicenter, trial randomized 266 patients to receive a QuaDS-QP2 stent
(4000 mg with an elution over 180d) or a bare stent. Follow-up
angiography at 6 months showed a significant reduction in restenosis in
the QuaDS-QP2 stent group (6.9% v. 36%). However, this trial has been
stopped by the safety committee because of an excessive adverse event rate
in the QuaDS-QP2 stent group of 10.2% – periprocedural myocardial
infarction and subacute stent thrombosis78.
Another step: biodegradable stents
Coronary stents exert their beneficial clinical effect within a relatively
narrow time frame. Stent scaffolding is needed from the acute
procedural phase (in case of threatened or actual vessel closure) until the
first 6 months after the procedure to overcome late negative vessel
remodelling. In the long-term perspective, metallic stents have potential
complications such as in-stent re-stenosis and the inaccessibility of the
lesion site for surgical revascularization. Thus stents made of bio-
degradable materials may be an ideal alternative.
Experimental data
The first requirement for polymeric materials in intracoronary stents is
biocompatibility. In animal studies, the biocompatibility of polymer
stents has been controversial suggesting that tissue incompatibility may
be a major obstacle.
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Marked inflammatory response after the implantation of 5 different
polymer-loaded stents (polyglycolic acid/polylactic acid, polycaprolactone,
polyhydroxybutyrate valerate, polyorthoester, and polyethyleneoxide/
polybutylene terephthalate) has been reported in a porcine coronary
model42. Thrombotic occlusion of polymeric stents was seen in other
experiments70.
In contrast, Zidar et al reported only a minimal inflammatory reaction
and minimal neo-intimal hyperplasia with the use of poly-l-lactic acid
(PLLA) stents in canine femoral arteries. In vitro data revealed a reduced
platelet adherence and thrombogenicity of the PLLA stent as compared
with slotted-tube stainless steel metallic stents70.
Investigational device: poly-l-lactic monopolymer Igaki-Tamai biodegradable stent 
(Igaki Medical Planning Co, Ltd)
The Igaki-Tamai stent is a coil stent made of a poly-l-lactic (PLLA)
monofilament (molecular mass, 183 kDa). PLLA has been used for
orthopaedic applications in humans and has generally been found to be
biocompatible. The stent is self-expanding with a zigzag helical design.
The stent length is 12 mm. The thickness of the stent strut is 0.17 mm.
In its expanded state, the stent covers 24% of the vessel area. The stent
has a radiopaque gold marker at both ends of the prosthesis. Stents are
mounted on standard angioplasty balloon catheters that are the same
size as the stent with diameters of 3.0, 3.5, and 4.0 mm (Figure 12). It
takes the stent 18–24 months to biodegrade fully.
Deployment of the stent is currently done with a balloon-expandable
covered sheath system through an 8 French guiding catheter. The stent
Ischaemic heart disease: therapeutic issues
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Fig. 12 Poly-l-lactic
monopolymer Igaki-
Tamai biodegradable
stent (Igaki Medical
Planning Co, Ltd.
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delivery balloon inflation is performed with a heated dye at 80°C using
a 30 s inflation at 6–14 atm. This temperature ensures adequate stent
expansion within 30 s and may minimize vessel injury caused by a
heated balloon. The stent continues to expand gradually to its original
size after deployment in vivo.
Clinical data
The first clinical data are available in 15 patients who underwent
elective coronary PLLA Igaki-Tamai stent implantation: 25 stents were
successfully implanted in 19 lesions. Angiographic success was achieved
in all procedures. No stent thrombosis and no major cardiac event
occurred within 30 days. Angiographically, both the re-stenosis rate and
target lesion revascularization rate were 10.5% at 6 months.
Intravascular ultrasound revealed no significant stent recoil at 1 day and
stent expansion at follow-up. No major cardiac event, except for repeat
angioplasty, developed within 6 months71.
Long-term data (12 months) of 63 lesions in 50 patients have been
previously presented. Angiographic analysis showed a good procedural
result with was a 12 ± 8% final diameter stenosis post-stent implantation.
At 6 months, diameter stenosis was 38 ± 23% and decreased slightly to 33
± 23% at 12 months. Subacute thrombosis occurred in one patient at day
5, but no other MI, urgent CABG, or death occurred over the 12 months72.
Limitations
Although the principle of stent implantation is well established and
although (most of) the applied drugs and polymers have been used in
clinical practice for many years, there is little experimental and only
preliminary clinical knowledge of the acute and long-term effects of drug-
eluting or biodegradable stents in coronary arteries. Thus, a number of
concerns and open questions have to be investigated in the future.
The concerns include drug toxicity as well as acute and late vascular
effects. A number of toxic effects are known for all drugs applied in
cancer therapy such haematological toxicity (neutropenia), neuro-
toxicity (peripheral neuropathy), hypersensitivity reactions, or cardiac
disturbances. However, these side-effects are described in patients
undergoing high-dose chemotherapy for a malignant disease with
plasma levels 100–1000 times higher (and over longer time periods)
than plasma levels that result from a local delivery. Another concern is
possible delayed wound healing and endothelialization. This would
increase thrombogenicity and the danger of (late) stent thrombosis.
Stent development and local drug delivery
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Further potential side-effects could be late positive remodelling and
aneurysmal formation. Thus the most suitable antithrombotic regimen
following drug-eluting and/or biodegradable stent implantation still has
to be evaluated.
A series of open questions exists on the mechanism of action and also
the design of local drug delivery systems and drug-eluting stents. Little
is known of specific pharmacokinetic issues. There is a paucity of data
on the most appropriate tissue concentration and the rate and duration
of drug-release over time. The tissue concentration is dependent on close
mechanical contact of the stent to the vascular tissue and on
physiological transport forces into the tissue. Hydrophobic drugs, like
paclitaxel, have greater variability in terms of drug delivery, while
hydrophilic drugs, like heparin, have less variability and achieve higher
local concentrations. Local concentrations and concentration gradients,
however, are crucial parameters for biological effects. The relationship
between vascular effects and physicochemical properties of the drug-
loaded stent is poorly understood. Drug distribution within the vessel
wall seems to be significantly affected by the stent expansion pattern
(uniform versus non-uniform)73.
Conclusions and future perspectives
Drug-eluting and biodegradable stents represent one of the fastest
growing fields in interventional cardiology today. However, many
unanswered questions still have to be resolved before determining the
potential of these techniques. Hopefully, after the completion of planned
and on-going trials many of these issues will be answered. Furthermore,
these new technologies will have to prove effective in the daily routine
of treating patients presenting with long lesions, small vessels, chronic
Ischaemic heart disease: therapeutic issues
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Fig. 13 Potential prevention of stent re-stenosis by non-invasively heating the stent, using
alternating magnetic fields. High frequency alternating magnetic fields cause hysteresis
phenomenon on the metallic stent, generating energy loss that appears as heat.
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occlusion, bifurcation, multi-vessel and/or left main stem disease or
acute myocardial infarction.
Stent development will investigate a variety of possibilities to resolve
the re-stenosis problem. Possibilities range from the further exploitation
of different classes of drugs which are potential candidates for the
inhibition of re-stenosis to the combination of biodegradability with
drug delivery, local gene therapy (e.g. local expression of proliferation
regulatory genes; transfer of cytotoxic genes, VEGF) or external heating
of stents (Fig. 13).
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